Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 4,103
Out of 5,099 analysts
81
Total ratings
30.67%
Success rate
-18.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $9.82 | +32.38% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $18.28 | +310.28% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $31.24 | -13.57% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $35.98 | +105.67% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $22.49 | -51.09% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $13.22 | +285.78% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.44 | +1,064.60% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.52 | +564.89% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $77.88 | -61.48% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.40 | +757.14% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $28.11 | +1,145.11% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.06 | +158.45% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $10.74 | +160.71% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $17.16 | +208.86% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $9.82
Upside: +32.38%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $18.28
Upside: +310.28%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $31.24
Upside: -13.57%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $35.98
Upside: +105.67%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $22.49
Upside: -51.09%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $13.22
Upside: +285.78%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.44
Upside: +1,064.60%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.52
Upside: +564.89%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $77.88
Upside: -61.48%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.40
Upside: +757.14%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $28.11
Upside: +1,145.11%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.06
Upside: +158.45%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $10.74
Upside: +160.71%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $17.16
Upside: +208.86%